Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With...
Hematopoietic/Lymphoid CancerAccelerated Phase Chronic Myelogenous Leukemia155 moreRATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignancies previously treated with donor stem cell transplant.
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young...
Acute Undifferentiated LeukemiaAtypical Chronic Myeloid Leukemia14 moreThis study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.
Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
Aggressive Systemic Mastocytosis (ASM)SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD)3 moreThe purpose of this study is to explore the key symptoms of individuals with systemic mastocytosis. Interviews of enrolled individuals will be conducted to learn about the disease symptoms and condition. The interview will last approximately 60 minutes and will be conducted by a trained interviewer, be audio-recorded (with patient consent), and all information provided by the patient will be treated confidentially and made anonymous so that it is non-identifiable. The interview may be conducted face-to-face, over the phone, or virtually via Skype, a free video conferencing program, depending upon the patient's geographic location. Patients will be compensated for their participating time. This is not a medication-related study, and no medication will be distributed or tested during this study. Participation in this study will not affect any treatment or assistance that a patient currently receives or may receive in the future.
Managed Access Programs for PKC412, Midostaurin
FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid LeukemiaAcute Myeloid Leukemia3 moreThe purpose of this registration is to list Managed Access Programs (MAPs) related to PKC4, Midostaurin.